Evidence map›Paper›PMID 37746298›Full record

ArticleFrontiers in oncology2023

Case Report:

Emmanuella Oyogoa, Lukas Streich, Philipp W Raess, Theodore Braun

Abstract readCase Reports
In one paragraph

Article in Frontiers in oncology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Emmanuella OyogoaDepartment of Medicine, Oregon Health & Science University, Portland, OR, United States.
Lukas StreichDepartment of Pathology, Oregon Health & Science University, Portland, OR, United States.
Philipp W RaessDepartment of Pathology, Oregon Health & Science University, Portland, OR, United States.
Theodore BraunDivision of Hematology & Medical Oncology, Oregon Health & Science University, Portland, OR, United States.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Although the majority of patients with chronic myeloid leukemia (CML) enjoy an excellent prognosis tyrosine kinase inhibitor (TKI) therapy, resistance remains a significant clinical problem. Resistance can arise from mutations in the kinase domain of ABL preventing drug binding, or due to ill-defined kinase-independent mechanisms. In this case report, we describe the case of a 27-year-old woman with a long-standing history of chronic phase (CP) CML who developed kinase-independent resistance with mutations in

Indexed as

ASXL1CMLCMML-APRUNX1systemic inflammatory and autoimmune diseasestyrosine kinase independent resistancetyrosine kinase inhibitors

Identifiers

PMID37746298
PMCPMC10513384

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.